Standard BioTools stockholders approved all seven proposals at a November 19, 2026 special meeting, including share issuance tied to the Merger with Treeline Biosciences. The approved charter amendment covers a reverse stock split at a ratio in the range from 1-for-20 to 1-for-40 and a name change to Treeline Biosciences, Inc. The Element Mass Cytometry divestiture was also approved, with 276,299,544 votes for.
LAB · Standard Biotools Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 75%
- Last earnings
- Aug 11, 2025
- Latest filing
- 10-Q · Nov 3
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Standard BioTools Inc. voluntarily supplemented merger disclosures after 15 demand letters and two stockholder complaints alleged omissions in materials for its Treeline merger, ahead of the November 19, 2026 stockholder meeting.
Standard BioTools expects its merger with Treeline Biosciences to close in the fourth quarter of 2026, with existing shareholders holding approximately 16% of the combined company. Stockholders are scheduled to vote on November 19, 2026.
Standard BioTools completed the sale of its Microfluidics business to ARCHIMED on November 3, 2026; the standalone business will operate as Biomark Scientific.
Standard BioTools agreed on June 6, 2026 to combine with Treeline Biosciences in an all-stock merger, with former Treeline stockholders expected to hold approximately 84% of the combined company. Stockholders will vote on the share issuance, a reverse stock split at a ratio in the range of 1-for-20 to 1-for-40, and the Element Mass Cytometry Divestiture. Element's purchase agreement was signed on September 30, 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$5.6M | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross margin percentage non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
| Non-GAAP gross profit non-GAAP | $23.52M | Six Months Ended June 30, 2026 | — |
| Non-GAAP operating expenses non-GAAP | $29.11M | Six Months Ended June 30, 2026 | — |
| Non-GAAP R&D operating expenses non-GAAP | $3.42M | Six Months Ended June 30, 2026 | — |
| Non-GAAP SG&A operating expenses non-GAAP | $25.7M | Six Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LAB
this stock
Standard Biotools Inc.
|
$249.11M | -50.7% | -2.4% | 1.9 | 0.5% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 19, 2026
- This year
- 31
Standard BioTools stockholders approved all seven proposals at a November 19, 2026 special meeting, including share issuance tied to the Merger with Treeline Biosciences. The approved charter amendment covers a reverse stock split at a ratio in the range from 1-for-20 to 1-for-40 and a name change to Treeline Biosciences, Inc. The Element Mass Cytometry divestiture was also approved, with 276,299,544 votes for.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LAB | -10.8% | +4.2% | -45.6% | +3.4% | -50.7% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -2.2% | +13.4% | -36.4% | +12.2% | -51.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.